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Purpose: This study was aimed to assess the outcome of radiotherapy and determine prognostic factors
for survival in breast cancer patients with clinically overt metastasis to the internal mammary lymph
node (IMNþ).
Methods: We retrospectively reviewed the medical records of 193 patients with IMN þ breast cancer
who received neoadjuvant chemotherapy (NAC), breast surgery without internal mammary lymph node
(IMN) dissection, and postoperative radiotherapy at 9 hospitals between 2009 and 2013. Breast-
conserving surgery or mastectomy was performed after taxane-based NAC. Radiotherapy was adminis-
tered to the whole breast/chest wall and regional nodes. IMN-covering radiotherapy was performed in
92.2% of patients with median dose of 58.4 Gy (range, 44.9e69.1 Gy). The overall survival (OS), disease-
free survival (DFS), and IMN failure-free survival (IMNFFS) were analyzed.
Results: After median follow-up of 71 months, 9 patients (4.7%) developed IMN failure and simultaneous
distant metastasis. The 5-year DFS, OS, and IMNFFS was 68.6%, 81.8%, and 95.3%, respectively. Non-triple-
negative breast cancer, Ki-67  10%, pathological complete response (CR) in tumor and axillary node, and
radiologic CR of IMN after NAC were significant factors for predicting higher DFS; however, IMN radiation
dose was not significant determinants for DFS. The 5-year DFS of patients with IMN-dose  50.0 Gy and
those with >50.0 Gy was 86.7% and 76.7%, respectively (p ¼ 0.41).
Conclusions: A multimodality strategy including NAC, breast surgery, and IMN-covering radiotherapy
was effective for patients with overt IMN þ breast cancer. Even without an IMN dissection, most patients
were IMN failure-free with an IMN-focusing radiotherapy.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ncology, Gangnam Severance
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r Ltd. This is an open access article1. Introduction
Lymphatic metastasis of breast cancer mainly occurs via the
axillary, transpectoral, and IMN chains [1]. More than 20% of the
lymphatics flow into the IMN while approximately 90% of the
breast lymphatics drain into the axillary lymph nodes (ALN) [2,3].
Clinically apparent IMNþ in the absence of ALN metastasis isunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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is staged as N3b [4]. Although the IMN is defined as a regional node
similar to the ALN, previous studies have suggested that breast
cancer involving IMN has a worse prognosis than that involving
ALN metastasis [5,6]. Nonetheless, in studies in which breast sur-
gery and effective adjuvant treatments were administered, patients
with IMN þ breast cancer could achieve favorable outcomes [7,8].
Although there are controversies regarding the negative prognostic
influence of IMNþ, there is increasing need to optimize manage-
ment for IMN þ breast cancer.
A study conducted in the 1960s showed that extended mas-
tectomy, including IMN dissection, did not improve breast cancer
survival compared to mastectomy alone [9]. Less than 40% of
IMN þ patients survived 5 years after the extended mastectomy in
the absence of adjuvant treatment [9]. Given the unsuccessful
outcome after IMN dissection, a multimodal treatment combining
breast surgery, IMN-encompassing radiotherapy, and systemic
therapies has been advocated for IMN þ breast cancer [8,10e14].
Considering that surgical removal of the IMN is not performed in
the multimodal strategy, radiotherapy is primarily responsible for
local control in the IMN region. In addition, given that neoadjuvant
chemotherapy (NAC) is increasingly used to treat locoregionally
advanced breast cancer [15], radiotherapy is needed to be adjusted
according to the response to NAC. However, no consensus has so far
been reached on the optimal radiotherapeutic approach for
IMN þ breast cancer. This study is aimed to assess the outcomes of
radiotherapy and define an optimal regimen for postoperative
radiotherapy in IMN þ breast cancer patients undergoing NAC
followed by breast surgery without IMN dissection.2. Materials and methods
We retrospectively reviewed the medical records of patients
with IMN þ breast cancer who received NAC, followed by breast
surgery and postoperative radiotherapy, at 9 hospitals in South
Korea between January 2009 and December 2013. The inclusion
criteriawere IMNþ breast cancer without distant organmetastasis,
curative breast surgery, and completion of planned NAC and
radiotherapy schedules. Patients underwent IMN dissection or
those in whom the radiologic response of the IMN after NAC could
not be assessed were excluded. IMNþ was defined as IMN
measuring 0.5 cm on breast magnetic resonance imaging (MRI)
before the initiation of NAC or confirmation of tumor deposit in the
IMN by fine needle aspiration (FNA) or core-needle biopsy.
The IMN size was determined by measuring the longest diam-
eter of the IMN on breast MRI. The IMN response to NAC was
evaluated by comparing the IMN size measured before NAC and
before breast surgery. The radiation dose to the IMN was converted
to an equivalent dose in 2 Gy fractions (EQD2) using the linear
quadratic model with a/b of 3.5 Gy.
After the treatment was completed, patients were followed up
according to the surveillance protocol of each institution. Outcome
data were collected for the following: disease status at last follow-
up visit, locoregional recurrence (LRR), distant metastasis (DM),
and death. Overall survival (OS) was defined as the interval be-
tween the date of NAC and the date of last follow-up or death.
Disease-free survival (DFS), IMN failure-free survival (IMNFFS),
LRR-free survival (LRRFS), and DM-free survival (DMFS) were
defined as the interval from the date of NAC to the date of cancer
recurrence, IMN recurrence, LRR, and DM, respectively. In patients
without disease recurrence, the DFS, IMNFFS, LRRFS, and DMFS
were calculated as the interval from the date of NAC until the date
of last follow-up or death.113The survival duration was estimated using the KaplaneMeier
method and the log-rank test was used to compare survival be-
tween groups with different variables. A receiver operating char-
acteristics (ROC) analysis was used to define the cut-off point in
continuous variables. The continuous variables were dichotomized
according to the cut-off point indicated by the ROC analysis. A
multivariate Cox stepwise regression model was used to access the
impact of variables on the survival outcomes. Variables with a
significance at p < 0.05 on univariate analysis were included in the
multivariable analysis. The p-values of <0.05 were considered sta-
tistically significant. Statistical analyses were performed using the
MedCalc Statistical Software version 19.3.1 (MedCalc Software Ltd,
Ostend, Belgium; https://www.medcalc.org; 2020). The Institu-
tional Review Board at the principal investigator’s hospital
approved this study and waived off the requirement of patient
informed consent.3. Results
3.1. Patient and treatment
In total, 193 patients with a median age of patients was 44 years
(range, 20e73 years) were include in this study. Patient charac-
teristics are shown in Table 1. All patients had undergone breast
MRI prior to initiation of NAC and breast surgery. Positron emission
tomography-computed tomography was performed in 166 patients
(96.4%) at time of breast cancer diagnosis. The median size of the
IMN was 0.8 cm (range, 0.2e2.0 cm) at initial breast cancer diag-
nosis. The distribution of the IMN size and cytologic results are
described in Table 2. After completion of NAC, 124 (64.2%) patients
showed radiologic complete response on breast MRI before breast
cancer surgery.
The clinical target volume (CTV) was contoured to include
whole breast (WB)/chest wall (CW) and/or regional lymph nodes.
Following areas were encompassed as the CTV: WB/CW alone in 2
patients (1.0%), WB/CW in conjunction with supraclavicular lymph
node (SCN) in 13 (6.7%), WB/CW with IMN in 7 (3.6%), and a
combination of WB/CW, SCN, and IMN in 171 (88.6%) patients. The
CTV for IMN was delineated in a region encompassing the first
three or fourth intercostal spaces longitudinally and margins
around IMN vessels mediolaterally. Radiation fields were modified
to adequately cover the CTV using three-dimensional conformal
radiotherapy (n ¼ 174) or intensity-modulated radiotherapy (IMRT,
n¼ 18). For IMRT, tomotherapy (n¼ 3) or volumetric modulated arc
therapy (n ¼ 15) was used. Radiation dose to the CTV was
50e68.4 Gy with a daily dose of 1.8e2.0 Gy (n ¼ 182) or
40.05e48 Gywith a daily dose of 2.67e3.2 Gy (n¼ 11). Accordingly,
the median EQD2 for each radiation field were as follows: 54 Gy
(range, 44e70 Gy) for the WB/CW field, 48 Gy (range, 0e58 Gy) for
the SCN field, and 50 Gy (range, 0e69 Gy) for the IMN field. The
IMN chains were included in the radiation field in 178 (92.2%) pa-
tients with a median EQD2 of 58.4 Gy (range, 44.9e69.1 Gy). The
remaining 15 (7.7%) patients did not undergo IMN-focusing radio-
therapy. There was a significant trend for applying a higher IMN
radiation dose (EQD2 > 50.0 Gy) in patients with TNBC, multiple
IMN adenopathy involving multiple intercostal spaces (ICS), IMN
size measuring  0.8 cm, or cytology-positive IMN (Table 3).
Further, 183 (94.8%) patients received taxane-containing agents
and all patients, except 1 patient, with ERþ and/or PR þ tumors
(n ¼ 93) underwent endocrine therapy. Among the patients with
ERþ and/or PR þ tumors, 66 (70.9%) received tamoxifen, 22 (26.6%)
received aromatase inhibitors, and 4 (4.3%) received other endo-
crine agents. Except 5 patients, all patients with HER2þ tumor
Table 1
Patient characteristics.
Characteristics Number of patients
(%)
Age (years) <40 68 (35.2)
40 125 (64.8)
Histologic grade 1e2 96 (49.7)
3 80 (41.5)
Unknown 17 (8.8)
Tumor subtype ERþ/or PRþ/HER2- 60 (31.1)
ERþ/or PRþ/HER2þ 33 (17.1)
ER-/PR-/HER2þ 35 (18.1)
ER-/PR-/HER2- 65 (33.7)
Ki-67 (%) of breast tumor 10% 45 (23.3)
>10% 148 (76.7)
cT stage 1e2 113 (58.5)
3e4 80 (41.5)
cN stage N2b 14 (7.3)
N3b 179 (92.7)
ypT stage ypT0 or ypTis 44 (22.8)
ypT1 or ypT2 118 (61.1)
ypT3 or ypT4 31 (16.1)
ypN stage ypN2b 87 (45.1)
ypN3b 106 (54.9)
ypStage ypTisN2b or ypT1N2b 41 (21.2)
Non- ypTis/T1N2b 152 (78.8)
Extent of IMN Single ICS 123 (63.7)
Multiple ICS 70 (36.3)
Size of IMN <0.8 cm 69 (35.8)
0.8 cm 124 (64.2)






Not done 118 (61.1)
IMN response to NAC Complete response 124 (64.2)
Residual IMN (þ) 69 (35.8)
Type of breast surgery Breast-conserving surgery 88 (45.6)
Mastectomy 105 (54.4)




EQD2 of the IMN1) 50.0 Gy 100 (51.8)
>50.0 Gy 93 (48.2)
Interval between surgery
and RT
37 days 100 (51.8)
>37 days 93 (48.2)
Abbreviations: ER: Estrogen receptor, PR: Progesterone receptor, HER2: Human
epidermal growth factor receptor type 2, IMN: Internal mammary node, NAC:
Neoadjuvant chemotherapy, ICS: Intercostal space, EQD2: Biologically equivalent
dose in 2 Gy fractions, RT: Radiotherapy.
1) The radiotherapy dose was calculated using the EQD2, assuming the a/b ratio of
3.5 Gy.
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Over the median follow-up of 71 months (range, 6e166
months), 64 (33.1%) patients developed disease recurrence. TheTable 2
Size of internal mammary lymph node and cytologic results.
Cytologic evaluation of the IMN Size of the IMN
<0.5 cm
Negative for metastasis 0 (0.0%)
Positive for metastasis 6 (100.0%)
Not done 0 (0.0%)
All 6 (100.0%)
Abbreviations: IMN: Internal mammary lymph node.
The long diameter of the internal mammary lymph node was measured on breast MRI pr
each patient.
114sites of recurrence were local site alone in 1 (0.5%) patient; regional
lymph nodes in 2 (1.0%) patients; regional and distant site in 18
(9.3%) patients; simultaneous local, regional, and distant sites in 6
(3.1%) patients; local and distant site in 6 (3.1%) patients; and
distant site alone in 31 (16.1%) patients. Nine (4.7%) had IMN
recurrence; 7 patients had IMN recurrences simultaneously with
DM, while 2 patients had IMN recurrences coincidently with local
and distant site failures. The 5-year DFS, OS, IMNFFS, LRRFS, and
DMFS were 68.6%, 81.8%, 95.3%, 82.5%, and 70.2%, respectively, and
the 10-year DFS, OS, IMNFFS, LRRFS, and DMFS were 62.6%, 70.2%,
93.6%, 81.0%, and 64.1%, respectively.
In univariate analyses for DFS, non-TNBC, Ki-67  10%, patho-
logic CR (ypCR) in the tumor and ALN (ypTisN2b or ypT0N2b),
radiologic CR of the IMN after NAC, BCS, and an interval between
breast surgery and radiotherapy of 37 days were significantly
associated with favorable DFS. In multivariate analysis, non-TNBC,
Ki-67  10%, ypCR in the tumor and ALN, radiologic CR in the
IMN, and BCS were significantly related to a higher DFS. To evaluate
the association between the IMN radiation dose and DFS, the sur-
vival of patients was compared according to the IMN EQD2
(Table 4). The DFS was not significantly different by IMN EQD2 in
most subgroups, except for thosewith TNBC. In patients with TNBC,
the 5-year DFSwas lower in the high IMN EQD2 (>50.0 Gy) than the
low IMN EQD2 (50.0 Gy) group (46.2% vs. 67.8%, p ¼ 0.03)
(Table 5). There were no significant factors associated with IMNFFS
(Supplementary Table 1).
4. Discussions
In this retrospective analysis of 193 patients from9 hospitals, we
found that patients with overt IMN þ breast cancer could achieve a
favorable outcome with a multimodality approach including NAC,
breast surgery and IMN-covering postoperative radiotherapy. Even
without IMN dissection, 93% patients were IMN failure free at the
10-year follow-up after the multimodal treatment. There was a
tendency to administer high IMN radiation doses in patients with
TNBC, multiple ICS-involving IMN adenopathy, and cytology-
positive IMNþ. However, the high IMN radiation dose was not
associated with improved outcome. Additionally, we found that
TNBC, high Ki-67, not achieving ypCR in the tumor and ALN, and
persistent IMN adenopathy after NAC were significant factors for
predicting unfavorable DFS. Therefore, our study suggests that
patients with these risk factors require further intensified locore-
gional and systemic therapies to improve breast cancer outcomes.
The risk of microscopic IMNþ is increased in patients with a
young age at diagnosis, ALNmetastasis, and inner quadrant-located
tumors [16e18]. According to studies in which IMN dissection was
conducted, the incidence of microscopic IMNþ was 4%e9% and
27%e29% in pN0 and pN þ patients, respectively [9,18]. Based on
studies showing improved breast cancer outcomes after prophy-
lactic IMN irradiation in patients with ALN metastasis [19e21], a
treatment strategy has been established to include elective IMN0.5e1.0 cm 1.1e1.5 cm 1.6e2.0 cm
14 (10.8%) 2 (4.2%) 0 (0.0%)
40 (30.8%) 10 (20.8%) 3 (33.3%)
76 (58.4%) 36 (75.0%) 6 (66.7%)
130 (100.0%) 48 (100.0%) 9 (100.0%)
ior to the initiation of neoadjuvant chemotherapy. The largest IMN was measured in
Table 3
Patient characteristics according to radiation dose to the internal mammary lymph node.
Characteristics No. Of patients (%) p-value
IMN EQD2  50.0 Gy (n ¼ 100) IMN EQD2 > 50.0 Gy (n ¼ 93)
Age <40 years 31 (45.6) 37 (54.4) 0.20
40 years 69 (55.2) 56 (44.8)
Tumor subtype Non-TNBC 74 (57.8) 54 (42.2) 0.01
TNBC1) 26 (40.0) 39 (60.0)
Ki-67 (%) 10% 23 (51.1) 22 (48.9) 0.91
>10% 77 (52.0) 71 (48.0)
cT stage 1e2 61 (54.0) 52 (46.0) 0.47
3e4 39 (48.7) 41 (51.3)
cN stage N2b 6 (42.9) 8 (57.1) 0.48
N3b 94 (52.5) 85 (47.5)
ypStage ypTisN2b or ypT1N2b 24 (58.5) 17 (41.5) 0.33
Non- ypTis/T1N2b 76 (50.0) 76 (50.0)
Extent of IMN Single ICS 71 (57.7) 52 (42.3) 0.02
Multiple ICS 29 (41.4) 41 (58.6)
IMN diameter <0.8 cm 24 (34.8) 45 (65.2) <0.01
0.8 cm 76 (61.3) 48 (38.7)
No. Of involved IMN Single 70 (59.3) 48 (40.7) <0.01
Multiple 30 (40.0) 45 (60.0)
Path þ IMN2) Negative or unknown 89 (66.4) 45 (33.6) <0.01
Positive 11 (18.6) 48 (81.4)
Residual IMN after NAC No residual 64 (51.6) 60 (48.4) 0.94
Residual (þ) 36 (52.2) 33 (47.8)
Type of surgery BCS 44 (50.0) 44 (50.0) 0.64
Mastectomy 56 (53.3) 49 (46.7)
Abbreviations: IMN: Internal mammary lymph node, EQD2: Biologically equivalent dose in 2 Gy fractions, TNBC: Triple-negative breast cancer, ICS: Intercostal
space, NAC: Neoadjuvant chemotherapy, BCS: Breast-conserving surgery.
1)TNBC was defined as ER-/PR-/HER2-on breast tumor immunohistochemistry.
2) Tumor deposit in the IMN assessed by fine-needle aspiration biopsy or core-needle biopsy was defined as Path þ IMN positivity.
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control occult microscopic IMNþ, a radiation dose of 45e50.4 Gy in
24e28 fractionations has been administered to the IMN chains
[19,21,23,24]. However, the optimal treatment is controversial for
patients with overt IMNþ. Considering that a greater radiation dose
is necessary to control macroscopic disease than in treating
microscopic tumor foci [25], it can be postulated that a high IMN
radiation dose is necessary to control overt IMNþ. Moreover, in
cases without IMN dissection, the radiation dose should be
adjusted to eliminate gross metastatic lesions, since radiotherapy is
a sole local treatment in patients with overt IMN þ breast cancer.
Several studies have reported the outcome of multimodal
treatment, excluding IMN dissection, in patients with clinically
apparent IMN þ breast cancer (Table 6) [8,11e14,26]. All previous
studies included <100 patients and the data were retrospectively
collected at a single institution. Of the tumors included in the
studies, 47%e73% were negative for hormone receptor expression.
Further, IMNþwas mostly determined by radiologic examinations;
only 2%e57% of the participants were diagnosed with IMN þ by
both radiologic findings and histopathologic evaluation of the IMN.
In addition, a radiation dose of 45.0e66.5 Gy was administered to
the IMN chains, and the amount of IMN radiation dose was deter-
mined at the discretion of the physician [8,11,12,14] or the IMN
response to NAC [26]. In a study by Zhang et al. a dose of 66 Gy was
prescribed to the IMN region in patients with residual radiographic
IMN adenopathy after NAC, while and IMN dose of 60 Gy was given
to patients showing complete radiologic response after NAC [26].
Except the study by Zhang et al. the dose prescription of IMN
radiotherapy was not guided by specific tumor characteristics. In
our study, patients with TNBC, small size IMN lymphadenopathy,
multiple ICS-involving IMN adenopathy, and cytology-positive
IMN þ tended to receive higher IMN dose than those without
these features. Given that small-size IMN adenopathy was more
likely to be evaluated by histopathological examination than large-
size IMN, the tendency of administering a higher IMN dose to115small-size IMN might attributed to the distribution pattern of
cytology-positive IMNþ in our study. This trend in radiotherapy
prescription suggests that the IMN characteristics at breast cancer
diagnosis influenced the IMN dose prescription in the participating
hospitals. However, the administered prescription scheme did not
offset the unfavorable outcome in patients with adverse risk fac-
tors. Moreover, an IMN dose >50 Gy (EQD2) was not associated
with improved DFS in our analysis.
Previously, there have been conflicting results regarding an as-
sociation between IMN radiation dose and disease control in pa-
tients with overt IMN þ breast cancer. In a study by Park et al.
administering of higher radiation doses to PET-positive IMN was
not associated with better outcomes [11]. The study included 12
patients with cN3b breast cancer and prescribed doses of
50.4e55.8 Gy to the PET-positive IMN region; of the 12 patients, 3
patients did not undergo IMN-covering radiotherapy. During a
median follow-up of 38 months, 1 out of the 9 patients who
received IMN-covering irradiation had IMN recurrence, while none
had IMN failure among the 3 patients without IMN-covering
radiotherapy (5-year IMNFFS, 88% vs. 100%, p ¼ 0.54). Based on
this result, the authors concluded that administering a higher ra-
diation dose to the PET-avid IMN was not associated with addi-
tional gains in the breast cancer outcome. However, the study had a
small sample size of only 12 patients. Moreover, no statistical
comparison of the tumor characteristics between the patients
receiving a high IMN dose and those without IMN-focusing radio-
therapy was conducted in the study. Contrary to the study of Park
et al. another study showed a significant association between IMN
radiation dose and breast cancer survival. In a study by Yang et al.
the DFS was significantly influenced by the IMN dose in patients
with large IMN adenopathy (1 cm) [8]. The 5-year DFS in patients
receiving a high IMN EQD2 (63.6 Gy) and low IMN EQD2
(<63.6 Gy) was 69.3% and 33.3%, respectively (p < 0.01). Although
such a dose-response relationship was only found in patients with
large IMN, the study suggested that there might be a subset of
Table 4
Prognostic factors for disease-free survival.
Characteristics No. Of pts 5-yr DFS (%) Univariate Multivariate HR (95% CI)
Age (years) <40 68 61.9 0.12 e e
40 125 72.2
Histologic type IDC 185 67.8 0.25 e e
Others 8 87.5
Tumor subtype Non-TNBC 128 75.8 <0.01 <0.01 2.6 (1.5e4.4)
TNBC1) 65 54.8
Ki-67 (%) 10% 45 93.2 <0.01 0.01 2.8 (1.3e6.2)
>10% 148 60.9
cT stage 1e2 113 72.9 0.19 e e
3e4 80 62.6
cN stage N2b 14 63.5 0.73 e e
N3b 179 69.1
ypStage ypTis or T0N2b 41 86.9 <0.01 0.01 3.2 (1.3e8.3)
Non-ypTis/T0N2b 152 63.8
IMN extent Single ICS 123 80.5 0.46 e e
Multiple ICS 70 82.2
No. Of involved IMN Single 118 80.6 0.47 e e
Multiple 75 82.0
Size of IMN <0.8 cm 69 77.8 0.03 e e
0.8 cm 124 63.6
Path þ IMN2) Negative or unknown 134 69.5 0.46 e e
Positive 59 66.6
Residual IMN No residual 124 76.1 <0.01 <0.01 2.3 (1.4e3.8)
after NAC Residual (þ) 69 55.5
Type of surgery BCS 88 80.3 <0.01 <0.01 2.3 (1.4e4.5)
Mastectomy 105 58.7
Axillary OP SLNBx 30 66.2 0.08 e e
ALND 163 82.5
EQD2 of IMN1) 50.0 Gy 100 86.7 0.41 e e
>50.0 Gy 93 76.7
OP to RT interval 37 days 100 76.6% 0.03 e e
>37 days 93 60.4%
Abbreviations: DFS: Disease-free survival, HR: Hazard ratio, CI: Confidence interval, IDC: Invasive ductal carcinoma, TNBC: Triple-negative breast cancer, IMN: Internal
mammary lymph node, ICS: Intercostal space, NAC: Neoadjuvant chemotherapy, BCS: Breast-conserving surgery, OP: Operation, SLNBx: Sentinel lymph node biopsy, ALND:
Axillary lymph node biopsy, EQD2: Biologically equivalent dose in 2 Gy fractions, RT: Radiotherapy.
1)TNBC was defined as ER-/PR-/HER2-on breast tumor immunohistochemistry.
2)Tumor deposit in the IMN assessed by fine-needle aspiration biopsy or core-needle biopsy was defined as Path þ IMN positivity.
Table 5
Impact of the radiotherapy dose to the internal mammary lymph node on disease-free survival.
Characteristics No 5-year DFS (%) p-value
IMN EQD2
 50.0 Gy (n ¼ 100)
IMN EQD2
50.0 Gy (n ¼ 93)
Tumor subtype Non-TNBC 128 73.6 79.0 0.19
TNBC1) 65 67.8 46.2 0.03
Ki-67 (%) 10% 45 91.3 95.0 0.31
>10% 148 65.7 57.4 0.13
ypStage ypTis or T0 N2b 41 85.8 87.8 0.93
Non-ypTis/T0N2b 152 67.6 60.0 0.48
Size of IMN <0.8 cm 69 82.5 75.3 0.99
0.8 cm 124 68.9 58.0 0.08
Path þ IMN2) Negative or unknown 134 70.6 67.6 0.99
Positive 59 81.8 62.4 0.34
Residual IMN after NAC No residual 124 75.9 76.3 0.91
Residual (þ) 69 65.5 44.8 0.15
Type of surgery BCS 88 81.1 79.5 0.95
Mastectomy 105 64.8 52.2 0.22
Abbreviations: DFS: Disease-free survival, IMN: Internal mammary lymph node, EQD2: Biologically equivalent dose in 2 Gy fractions, TNBC: Triple-negative breast cancer,
NAC: Neoadjuvant chemotherapy, BCS: Breast-conserving surgery.
1)TNBC was defined as ER-/PR-/HER2-on breast tumor immunohistochemistry.
2)Tumor deposit in the IMN assessed by fine-needle aspiration biopsy or core-needle biopsy was defined as Path þ IMN positivity.
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In our analysis, an IMN EQD2 > 50 Gy was not associated with
improved DFS. The 5-year DFS rate tended to be lower in patients
receiving an IMN dose of >50 Gy than those receiving an IMN dose
50 Gy, although there was no statistical significance. Moreover,
among patients with TNBC, the DFS was significantly inferior in116patients with an IMN dose of >50 Gy compared to those with
50.0 Gy. Among patients with TNBC, a high IMN dose was more
frequently given to cases with an IMN measuring <0.8 cm and
cytology-positive IMNþ (Supplementary Table 2). Such imbalances
in tumor characteristics between the IMN dose groups might
contribute to the inverse relationship between the IMN dose and
Table 6























12 38 0% 58.0% NAC-OP-RT 50.4 Gy (45.0e66.4 Gy) NR 5.5% DFS 67%, OS
79%




19 38 0% 73.7% NAC-OP-RT (78.9%) or OP-
RT-CTx (21.1%)
50.4 Gy (45.0e64.4 Gy) NR 0% NR
Kim et al.
[14]








84 58 48% 47.6% NAC-OP-RT (78.6%) or OP-
RT-CTx (21.4%)
62.5 Gy (50.0e66.5 Gy) NR 2.4% DFS 72%, OS
81%
Abbreviations: FU: Follow-up, IMN: Internal mammary lymph node, HR: Hormone receptor, CR: Complete response, OP: Operation, RT: Radiotherapy, CTx: Chemotherapy, fx:
Fractionations, NR: Not reported, DFS: Disease-free survival, OS: Overall survival, NAC: Neoadjuvant chemotherapy.
a Dissection of the internal mammary lymph node was not performed in any study.
b Response of the IMN was assessed based on imaging studies.
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were not significant adverse factors for DFS in this study, other
factors could have contributed to the inferior outcome in patients
with TNBC administered a high IMN dose. In addition, an insignif-
icant inverse association between the IMN dose and DFS was found
in patients with other factors, such as Ki-67 > 10%, non-ypCR in the
tumor and ALN, the IMN measuring 0.8 cm, cytology-positive
IMNþ, and radiological residual IMN after NAC. As most of these
factors were analyzed as risk determinants for inferior DFS in our
study, it is assumed that a high IMN dose could not negate the
adverse effect of the prognostic factors. However, since multiple
factors were differently distributed between the IMN dose groups,
it is difficult to conclude that escalating the IMN dose is unnec-
essary for patients with overt IMN þ breast cancer. Further studies
are needed to provide solid evidence for optimizing the IMN radi-
ation dose in the management of IMN þ breast cancer.
The tumor subtype and response to NAC were found to be sig-
nificant prognostic factors of DFS in our study. In addition, non-
TNBC subtype, Ki-67 < 10%, disappearance of IMN adenopathy af-
ter NAC, and achieving ypCR in the tumor and ALN were predictive
of favorable DFS. In particular, given that patients with ypCR in the
tumor and ALN had a 5-year DFS rate of 85.8% with an IMN dose of
50.0 Gy, it is possible to minimize the IMN radiation dose for
patients with the favorable features. Moreover, patients with a poor
response to NAC and an aggressive tumor type, such as TNBC or
high Ki-67, are thought to need more intensive treatment.
Considering that most patients included in our study received
taxane-based chemotherapy, more potent agents than the con-
ventional drug might be necessary for patients with the above-
mentioned adverse features. In addition, although no IMN radiation
dose-outcome relationship was found in this analysis, the efficacy
of high-dose IMN irradiation should be tested in patients with the
adverse factors in future studies.
The current study has limitations. First, as the data were retro-
spectively collected from 9 hospitals, some of the variables were
missing; for example, not all patients had information regarding
nuclear grade of the tumor. Therefore, the prognostic effect of the
nuclear grade was not analyzed in this study. Furthermore,
treatment-related toxicities could not be evaluated since the details
were not available. Lastly, since the IMN dose was decided based on
the physician’s preference, there were considerable differences in
the tumor characteristics between the IMN dose groups; therefore,
the impact of the IMN dose could not be objectively assessed. Even
with these limitations, this study provides important information
regarding the outcomes and prognostic factors in patients with117IMN þ breast cancer after multimodality treatment.
5. Conclusions
In conclusion, a multimodality strategy including NAC and
breast surgery, followed by IMN-covering radiotherapy was an
effective treatment for patients with IMN þ breast cancer. Even
without IMN dissection, most patients were IMN failure free with
an IMN-focusing radiotherapy. Patients with a non-TNBC subtype,
low Ki-67, ypCR in the tumor and ALN, and complete radiologic
response of IMN adenopathy after NAC were significant prognostic
factors for favorable DFS. Therefore, these factors might help
stratify the IMN radiation dose for patients with overt IMNþ breast
cancer.
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